开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2024-04-16 小胖子罗军来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：中药单体
经验分享：不收植物提取小分子的文章了，让改投到子刊

80 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2020-12-12 ms1000001706153386

审稿速度:1.0 | 投稿命中率:50.0
经验分享：一审15天，一周修回，2小时后accept，效率奇高

457 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2022-07-24 石烽

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：主动脉夹层
经验分享：5.3 Submitted to Journal
5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
5.10 Under Review
6.10 Required Reviews Completed
6.12 Decision in Process
6.14 Major Revise (20天期限)
7.2 Resubmitted to Journal
7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
7.11 Under Review
7.20 Required Reviews Completed
7.20 Decision in Process
7.23 Accept
7.23 Pre-proof online (DOI )
要点：
1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。
2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。
3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核
祝各位的Paper早日Accept !!!

203 42

展开42条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2024-07-08 ms5000000841668784 来自山东省

请问这个和CELL DEATH & DISEASE哪个认可度更高一点?

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2024-06-18 ds666888 来自四川省

审稿速度:1.0
经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运

69 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2024-02-28 不死鸟的飞翔来自重庆

偏重的研究方向：肿瘤
经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收

87 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2024-04-17 ms4000000344618620 来自浙江省

这个杂志今年为什么掉到中科院医学2区呢，降区很突然

70 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2021-10-29 ms5000001081306170

投稿命中率:50.0
经验分享：第一篇文章投这杂志就中了，😀

126 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2023-11-07 ms7000001072468055 来自北京

请问综述的checklist有模板吗？

89 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198813, encodeId=96182198813b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：不收植物提取小分子的文章了，让改投到子刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Tue Apr 16 15:04:05 CST 2024, time=2024-04-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=42, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213880, encodeId=81d6221388068, content=请问这个和CELL DEATH & DISEASE哪个认可度更高一点?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2c05566607, createdName=ms5000000841668784, createdTime=Mon Jul 08 13:19:30 CST 2024, time=2024-07-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210561, encodeId=db30221056135, content=审稿速度:1.0 经验分享：投稿半月后小修，一个好评一个差评，已返修，希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Tue Jun 18 18:55:39 CST 2024, time=2024-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198928, encodeId=cfdd2198928e0, content=这个杂志今年为什么掉到中科院医学2区呢，降区很突然, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0d515571355, createdName=ms4000000344618620, createdTime=Wed Apr 17 11:23:58 CST 2024, time=2024-04-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1064984, encodeId=c30a106498462, content=投稿命中率:50.0 经验分享：第一篇文章投这杂志就中了，😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1a9d5478170, createdName=ms5000001081306170, createdTime=Fri Oct 29 14:38:41 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2167251, encodeId=70cf216e25160, content=请问综述的checklist有模板吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07035603044, createdName=ms7000001072468055, createdTime=Tue Nov 07 17:36:45 CST 2023, time=2023-11-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省)]

2023-06-03 1473ac4am82暂无昵称来自四川省

偏重的研究方向：肿瘤
经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命

124 9

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务